Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11448478 | PMC |
| http://dx.doi.org/10.1038/s41408-024-01151-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Relevance and Prognostic Value of the Triple A (AAA) Score in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX).
Eur J Haematol
September 2025
Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I-Sapienza University, Rome, Italy.
Triple A Plus (AAA) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients.
Am J Hematol
September 2025
CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy.
Survival prediction models in essential thrombocythemia (ET) include the International Prognostic Scoring System (IPSET) and the more recently introduced triple-A (AAA) prognostic score. The latter enlists age and absolute neutrophil (ANC) and lymphocyte (ALC) counts as risk variables. In the current study, a Mayo Clinic discovery cohort of 658 patients with ET was used to identify AAA-independent risk variables.
View Article and Find Full Text PDFA Comprehensive Analysis of the Abdominal Aortic Aneurysm Growth Rate in the Spanish Population.
J Clin Med
July 2025
Unit of Genomics of Complex Disease, Institut de Recerca Sant Pau, IR SANT PAU, 08041 Barcelona, Spain.
The risk of Abdominal Aortic Aneurysm (AAA) rupture is associated with the aneurysm size and growth rate. This study aims to provide a global description of growth rates per intervals of AAA diameter size for individuals in the Spanish population, to understand possible comorbidities associated with growth rate variability, and to assess practitioners on safe follow-up visits for AAA patients. We present the Triple-A Barcelona Study (TABS), a new hospital-based longitudinal study recruiting consecutive individuals with AAAs in Barcelona.
View Article and Find Full Text PDFReal-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study.
Clin Transl Oncol
July 2025
Oncology Service, Fundación Instituto Valenciano de Oncología (IVO), Valencia, Spain.
Purpose: Maintenance avelumab has shown improved overall survival compared to chemotherapy alone in first-line treatment of advanced urothelial carcinoma. This study evaluates real-world evidence of avelumab as first-line maintenance therapy in patients with locally advanced or metastatic urothelial carcinoma (la/mUC).
Methods/patients: This was a multicenter, observational, retrospective and prospective study conducted in 22 Spanish centers.
Treatment strategies for triple-negative primary breast cancer in older women: a systematic review.
JNCI Cancer Spectr
April 2025
Medical School, University of Cambridge, Cambridge, United Kingdom.
Background: Although the relative proportion of triple-negative breast cancer decreases with age, its prevalence is rising with an aging population. This study examined real-world treatment practices, whether age in older women with triple-negative breast cancer affects therapy and outcomes, focusing on the potentially curable nature of early-stage triple-negative breast cancer.
Methods: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses, PRISMA-compliant search using population, intervention, comparison, outcomes criteria identified literature from 2014 to 2023 across 5 databases (MEDLINE, Embase, PubMed, Web of Science, and Scopus), focusing on women aged 65 years and older with early-stage triple-negative breast cancer.